Silencing miR-454 suppresses cell proliferation, migration and invasion via directly targeting MECP2 in renal cell carcinoma.

Liu, Huan; Liu, Qun-Long; Zhai, Ting-Shuai; Lu, Jun; Dong, Yun-Ze; Xu, Yun-Fei

Liu, Huan; Liu, Qun-Long; Zhai, Ting-Shuai; Lu, Jun; Dong, Yun-Ze; Xu, Yun-Fei.

Afiliación

Liu H; Department of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University Shanghai 200072, China.
Liu QL; Department of Urology, Shanghai Tenth People's Hospital, Nanjing Medical University Nanjing 210029, China.
Zhai TS; Department of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University Shanghai 200072, China.
Lu J; Department of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University Shanghai 200072, China.
Dong YZ; Department of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University Shanghai 200072, China.
Xu YF; Department of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University Shanghai 200072, China.

Am J Transl Res ; 12(8): 4277-4289, 2020.

Article en En | MEDLINE | ID: mdl-32913504

Palabras clave

MECP2; miR-454; oncogene; renal cell cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Am J Transl Res Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google